Richard Lowenthal
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Richard Lowenthal
Richard Lowenthal is recorded as CEO at ARS Pharmaceuticals, Inc. (SPRY). ARS Pharmaceuticals, Inc. reported in an 8-K filed July 17, 2026 that Richard Lowenthal resigned as member of the Board of Directors, effective July 15, 2026. ARS Pharmaceuticals, Inc. reported in an 8-K filed November 8, 2022 that Richard Lowenthal was appointed President, Chief Executive Officer and Class II Director, effective November 8, 2022. The proxy statement of ARS Pharmaceuticals, Inc. reports total compensation of $7,174,995 for Richard Lowenthal in fiscal 2024, including a base salary of $651,000. Disclosed compensation is on record for 3 fiscal years. Richard Lowenthal has spoken on 6 earnings calls across 1 company, most recently for ARS Pharmaceuticals, Inc. on March 9, 2026.
“On July 15, 2026, Richard Lowenthal resigned as a member of the Board of Directors (the "Board") of ARS Pharmaceuticals, Inc. (the "Company"), effective immediately.”
“At the effective time of the Merger, the Company's board of directors (and its committees) and executive officers were reconstituted to include the following directors and executive officers”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
-
Start not stated–2026-07-06
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at ARS Pharmaceuticals, Inc.
Other people whose current roles at this company are on record from its filings.
- Donn Casale CEO, Board Member
- Rich Lowenthal CEO
- Pratik Shah Chairman
- Kathleen Scott CFO
- Russ Hawkinson CFO
- Brian Dorsey COO
- Brenton L. Saunders Board Member
- Jonathan S. Leff Board Member
- Laura Shawver Board Member
- Michael Kelly Board Member
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | ARS Pharmaceuticals, Inc. (SPRY) | M.S., MSEL President and Chief Executive Officer | $651,000 | $7,174,995 |
| 2023 | ARS Pharmaceuticals, Inc. (SPRY) | M.S., MSEL President and Chief Executive Officer | $620,000 | $10,039,096 |
| 2022 | ARS Pharmaceuticals, Inc. (SPRY) | M.S., MSEL President and Chief Executive Officer | $74,630 | $476,343 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.